…is study examined whether therapy with a non-mitogenic, non-activating anti-CD3 mAb (G4.18) alone, or in combination with the T(h)2 cytokines, could inhibit induction or facilitate recovery from experimental allergic encephalomyelitis (EAE) in Lewis rats. G4.18, but not rIL-4, rI…

…expression was measured using 125I-labeled anti-rat ICAM-1 monoclonal antibody (MAb) and an isotype-matched control MAb labeled with 131I (to correct for nonspecific accumulation of the binding MAb). Under baseline conditions, ICAM-1 MAb binding was observed in all organs. The bi…

…athogenesis will be determining if the presence of cross-reacting T cells, presumably generated by other coronaviruses, play a role in the outcome of SARS-CoV-2 infection. 2. Antibody responses against SARS-CoV-2 Antibody responses to pathogens can be measured using assays that d…

…ncy use authorization was given to several anti-SARS-CoV-2 monoclonal antibody (mAb) therapies for the treatment of mild-to-moderate COVID-19 in patients with a high risk of progressing to severe disease. Monoclonal antibodies used to treat SARS-CoV-2 target the spike protein of …

… applied at RT for 2 hours. The primary antibodies used were anti-β III tubulin mAb (mouse, 1∶100, Santa Cruz); anti-glial fibrillary acidic protein (GFAP) mAb (mouse, 1∶250, BD Pharmingen); anti-S100 mAb (mouse, 1∶200, Millipore); anti-p75 NTR mAb (rabbit, 1∶3200, Cell Signaling…

…ontracts have not been made public, the developer for these three sites will be MAB Corporation, a Melbourne-based international property developer with 20+ years’ experience in providing affordable housing on the peri-urban fringe and high-end inner-city apartments. To date, MAB…

… completely neutralized by treatment with anti-murine IL-3 monoclonal antibody (mAb). When BCG-ILNC were treated with anti-Thy 1.2 or anti-Lyt 1.2 mAb followed by complement, IL-3 was not produced in the culture fluids. However, IL-3 in the culture fluids was detected when BCG-IL…

…ack of antibody avidity or affinity. We measured levels of vaccine-specific plasmablasts by ELISPOT 1 week after immunization of young and elderly adults with inactivated seasonal influenza vaccine. Plasmablast-derived polyclonal antibodies (PPAbs) were generated from bulk-cultur…

…ed with either secondary antibody alone (control, in black) or first with mouse mAbs (in gray) for α v β 3 (Axum-4), α v β 5 (Alula), α v β 6 (3G9), or α v β 8 (Adwa11), all generated by immunizing knockout mice with integrin subunits. (B) Co-IP and WB of cell lysates of isolated…

… acetone, permeabilized with TritonX-100, stained with Alexa-488-conjugated 1D4 mAb, and subjected to confocal microscopy. A ) Representative Alexa-488-conjugated 1D4 mAb fluorescent image resulting from IHC of an L4 TG animal expressing (h)Mo in neurons. 1D4 mAb stained the vent…

…c proteins, urinary albumin variants, charge variants of monoclonal antibodies (mAbs), and large-scale TDP of complex proteomes. Technical Development of cIEF-MS CE-MS Interface Online hyphenation of cIEF and ESI-MS requires a CE-MS interface that can establish electrical continu…

…r targeted therapies. UC-961 is a first-in-class humanized monoclonal antibody (mAb) that binds the extracellular domain of ROR1. In this paper we outline some of the preclinical studies leading to an investigation new drug (IND) designation, enabling clinical studies in patients…

Background: Monoclonal antibody (mAb) 6G5j is a novel anti-CEACAM monoclonal antibody. Our aim was to investigate mAb 6G5j binding characteristics and to validate fluorescence targeting of colorectal tumors and metastases in patient derived orthotopic xenograft (PDOX) models with…

…tibody (R & D Systems) or an anti-apoB-100 antibody [mouse monoclonal antibody (mAb) MB47 ( 19 ) specific for human apoB-100]. The membrane was then washed and incubated with a secondary HRP-conjugated antibody directed against the respective primary antibody, incubated with ECL-…

… examined the cytotoxic activity of venetoclax in combination with an anti-ROR1 mAb, cirmtuzumab. We found that cirmtuzumab could enhance the in vitro cytotoxicity of venetoclcax for CLL cells with high-level ROR1. This suggests that combining agents that target ROR1 and Bcl2 may…